Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique

European Journal of Cancer

Volumn 42, Issue 17, 2006, Pages 3073-3078

  Salmon, Howard W ^a   Mladinich, Christopher ^b   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

CA4P; Caki 1; Kidney; Mouse; OXi4053; Renal cell carcinoma; Vascular targeting

Indexed keywords

CA 4P; COMBRETASTATIN A1 PHOSPHATE; SILICON; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOLOGY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR NECROSIS; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; DIPHOSPHATES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; SILICON; STILBENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 33750496600     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.06.016     Document Type: Article

References (29)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA-Cancer J Clin 55 (2005) 10-30
2. Delahunt B., Kittelson J.M., McCredie M.R., Reeve A.E., Stewart J.H., and Bilous A.M. Prognostic importance of tumour size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumour categories and comparison with other prognostic parameters. Cancer 94 (2002) 658-664
3. Lau W.K., Cheville J.C., Blute M.L., Weaver A.L., and Zincke H. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 59 (2002) 532-537
4. Tsui K.H., Shvarts O., Smith R.B., Figlin R., de Kernion J.B., and Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumours. J Urol 163 (2000) 426-430
5. Drevs J., Loser R., Rattel B., and Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 23 (2003) 4853-4858
6. Bugajski A., Nowogrodzka-Zagorska M., Lenko J., and Miodonski A.J. Angiomorphology of the human renal clear cell carcinoma. A light and scanning electron microscopic study. Virchows Arch. A Pathol. Anat. Histopathol. 415 (1989) 103-113
7. Siemann D.W., Chaplin D.J., and Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004) 2491-2499
8. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10 (2004) 415-427
9. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metast Rev 9 (1990) 267-282
10. Tozer G.M., Kanthou C., and Baguley B.C. Disrupting tumour blood vessels. Nat Rev Cancer 5 (2005) 423-435
11. Folkman J. Tumour angiogensis: role in regulation of tumour growth. Symp Soc Dev Biol 30 (1974) 43-52
12. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23 (1984) 217-225
13. Grosios K., Holwell S.E., McGown A.T., Pettit G.R., and Bibby M.C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81 (1999) 1318-1327
14. Kanthou C., and Tozer G.M. The tumour vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99 (2002) 2060-2069
15. Tozer G.M., Prise V.E., Wilson J., et al. Mechanisms associated with tumour vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61 (2001) 6413-6422
16. Siemann D.W. Therapeutic strategies that selectively target and disrupt established tumour vasculature. Hematol Oncol Clin N Am 18 (2004) 1023-1037 [viii]
17. Young S.L., and Chaplin D.J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Invest Drug 13 (2004) 1171-1182
18. Bilenker J.H., Flaherty K.T., Rosen M., et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11 (2005) 1527-1533
19. Chaplin D.J., Pettit G.R., and Hill S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 19 (1999) 189-195
20. Hua J., Sheng Y., Pinney K.G., et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumour activity in comparison to combretastatin A-4 phosphate. Anticancer Res 23 (2003) 1433-1440
21. Kirwan I.G., Loadman P.M., Swaine D.J., et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin Cancer Res 10 (2004) 1446-1453
22. Shnyder S.D., Cooper P.A., Pettit G.R., Lippert III J.W., and Bibby M.C. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 23 (2003) 1619-1623
23. Rojiani A.M., and Rojiani M.V. Morphologic manifestations of vascular-disrupting agents in preclinical models. In: Siemann D.W. (Ed). Vascular-targeted therapies in oncology (2006), Wiley, London 81-94
24. Salmon H.W., Mladinich C., and Siemann D.W. Evaluations of the renal cell carcinoma model caki-1 using a silicon based microvascular casting technique. Technol Cancer Res Treat 5 (2006) 45-50
25. Rajon D.A., and Bolch W.E. Marching cube algorithm: review and trilinear interpolation adaptation for image-based dosimetric models. Comput Med Imaging Graph 27 (2003) 411-435
26. Rathmell W.K., Godley P.A., and Rini B.I. Renal cell carcinoma. Curr Opin Oncol 17 (2005) 261-267
27. Denekamp J., and Hobson B. Endothelial-cell proliferation in experimental tumours. Br J Cancer 46 (1982) 711-720
28. Salmon H.W., and Siemann D.W. Impact of the second generation vascular disrupting agent OXi4503 on tumour vascularity. Clin Cancer Res 12 (2006) 4090-4094
29. Chaplin DJ, Dougherty G, Siemann DW. Vascular disrupting agents. In: Abbruzzese JL, Davis DW, Herbst RS, editors. Antiangiogenic cancer therapy. CRC Press [in press].